Drug Discovery

Sponsor: LonzaIn this GEN webinar, we will hear about some of the latest advances in high-throughput analytics, with particular attention on the High-Throughput Impurity Detection platform for automated impurity quantitation from Lonza.

Sponsor: Solentim REGISTER NOW Broadcast Date: October 3, 2019 Time: 8:00 am PT, 11:00 am ET, 16:00 GMT, 17:00 CET Successful cell line development (CLD) for the production of...

Sponsor: SartoriusIn this GEN webinar, sponsored by Sartorius, we will hear from two members of the clinical development and discovery research teams at Inovio. We will learn about the novel DNA-encoded monoclonal antibody (dMab™) technology and how it is being employed for cancer therapies. Additionally, our presenters will describe some current pre-clinical work using DNA-encoded immune cell engagers (DICE).

Sponsored by: 3DS Dassault Systemes REGISTER NOW Broadcast Date: February 5, 2019 Time: 8:00 am PT, 11:00 am ET, 17:00 CET Antibody-drug conjugates (ADCs) were initially developed to provide a selective targeting...

Sponsor: RedShiftBio REGISTER NOW Broadcast Date: September 26, 2019 Time: 8:00 am PT, 11:00 am ET, 17:00 CET High hydrostatic pressure has been shown to act as a thermodynamic...

Sponsor: CorningIn this GEN webinar, sponsored by Corning, we will hear from two investigators who are employing organoids and spheroids in their respective research endeavors.

Sponsor: CarterraIn this GEN webinar, sponsored by Carterra, we will demonstrate how modern day high-throughput surface plasmon resonance (HT-SPR™) has facilitated a paradigm shift in antibody screening, enabling higher information content assays to be conducted earlier in the research pipeline to streamline lead selection. This essentially combines screening and detailed characterization in the same step, condensing months of work into days.

Sponsor: R&D SystemsIn TODAY's webinar, sponsored by R&D Systems, we will learn about the cellular and systemic conditions that regulate the hyper-inflammatory condition known as cytokine storm syndrome (CSS). This disorder has seen renewed interest, as it has been associated with a number of SARS-CoV-2 infections, an area that will also be discussed.

The top 15 immuno-oncology collaborations' total value of all 15 ranked collaborations is approximately $30 billion.

Scientists at Texas A&M University have identified a region in the brain that is involved in inhibiting fear, and which could feasibly lead to...